1. Home
  2. INTS vs SYNX Comparison

INTS vs SYNX Comparison

Compare INTS & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • SYNX
  • Stock Information
  • Founded
  • INTS 2012
  • SYNX 2005
  • Country
  • INTS United States
  • SYNX Israel
  • Employees
  • INTS N/A
  • SYNX N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • SYNX
  • Sector
  • INTS Health Care
  • SYNX
  • Exchange
  • INTS Nasdaq
  • SYNX Nasdaq
  • Market Cap
  • INTS 10.9M
  • SYNX 11.3M
  • IPO Year
  • INTS 2023
  • SYNX 2024
  • Fundamental
  • Price
  • INTS $0.23
  • SYNX $1.60
  • Analyst Decision
  • INTS Strong Buy
  • SYNX
  • Analyst Count
  • INTS 4
  • SYNX 0
  • Target Price
  • INTS $4.50
  • SYNX N/A
  • AVG Volume (30 Days)
  • INTS 4.0M
  • SYNX 120.9K
  • Earning Date
  • INTS 11-12-2025
  • SYNX 10-02-2025
  • Dividend Yield
  • INTS N/A
  • SYNX N/A
  • EPS Growth
  • INTS N/A
  • SYNX N/A
  • EPS
  • INTS N/A
  • SYNX N/A
  • Revenue
  • INTS N/A
  • SYNX $9,094,000.00
  • Revenue This Year
  • INTS N/A
  • SYNX $32.35
  • Revenue Next Year
  • INTS N/A
  • SYNX N/A
  • P/E Ratio
  • INTS N/A
  • SYNX N/A
  • Revenue Growth
  • INTS N/A
  • SYNX 19.14
  • 52 Week Low
  • INTS $0.19
  • SYNX $1.41
  • 52 Week High
  • INTS $4.30
  • SYNX $6.49
  • Technical
  • Relative Strength Index (RSI)
  • INTS 32.86
  • SYNX 45.77
  • Support Level
  • INTS $0.27
  • SYNX $1.41
  • Resistance Level
  • INTS $0.30
  • SYNX $1.83
  • Average True Range (ATR)
  • INTS 0.02
  • SYNX 0.16
  • MACD
  • INTS -0.00
  • SYNX -0.00
  • Stochastic Oscillator
  • INTS 6.39
  • SYNX 25.00

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

Share on Social Networks: